3.4.22.B50: papain-like proteinase 2
This is an abbreviated version!
For detailed information about papain-like proteinase 2, go to the full flat file.
Word Map on EC 3.4.22.B50
-
3.4.22.B50
-
polyproteins
-
replicase
-
coronaviruses
-
3clpro
-
isg15
-
3c-like
-
mhv-a59
-
nsp3
-
coronaviral
-
pp1ab
-
medicine
-
drug development
- 3.4.22.B50
- polyproteins
-
replicase
- coronaviruses
- 3clpro
- isg15
-
3c-like
-
mhv-a59
- nsp3
- coronaviral
- pp1ab
- medicine
- drug development
Reaction
responsible for the cleavages located at the N-terminus of the replicase polyprotein =
Synonyms
Erv-C, ervatamin-C, mouse hepatitis virus papain-like proteinase 2, papain-like accessory protease, papain-like cysteine proteinase, papain-like protease, papain-like protease domain 2, papain-like proteinase, PL2-PRO, PL2pro, PLP-2, PLP2, PLpro, SARS-coronavirus papain-like protease, SARS-CoV papain-like protease, SARS-CoV PLpro, severe acute respiratory syndrome coronavirus papain-like protease
ECTree
Advanced search results
Engineering
Engineering on EC 3.4.22.B50 - papain-like proteinase 2
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
C1651A
C1732A
-
encodes a substitution of a cysteine residue, predicted to be critical for zinc binding
D1826A
-
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues
C1651A
C1732A
-
encodes a substitution of a cysteine residue, predicted to be critical for zinc binding
-
D1826A
-
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues
-
I353R
the mutant exhibits about 40fold reduction in specificity toward ubiquitin compared to the wild type while the activity toward RLRGG-7-amido-4-methylcoumarin is essentially unaltered
I353W
the mutant exhibits about 10fold reduction in specificity toward ubiquitin compared to the wild type while the activity toward RLRGG-7-amido-4-methylcoumarin is essentially unaltered
T312A/I313V/I353R
C1729A
the mutant shows reduced interferon antagonistic activity compared to that of the wild type enzyme
D1901A
the mutant almost completely loses interferon antagonistic activity compared to that of the wild type enzyme
H1888A
the mutant almost completely loses interferon antagonistic activity compared to that of the wild type enzyme
T39W
mutation enhances hydrolysis of the SARS-CoV-derived peptidyl substrate Dabcyl-FRLKGGAPIKGV-Edans
C112S
D165A
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
E168A
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
E168D
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
E168R
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
L163Q
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
Y265A
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
Y265F
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme
Y274A
site-directed mutagenesis, inactive mutant
A67Y
the mutation enhances the catalytic efficiency of the enzyme about 8fold while the thermostability of the mutant enzyme remains unchanged. The specific activity against azo-casein is almost 2.4 times higher than wild type
S32T
the mutation enhances the catalytic efficiency of the enzyme about 8fold while the thermostability of the mutant enzyme remains unchanged
S32T/A67Y
the mutations enhance the catalytic efficiency of the enzyme about 8fold while the thermostability of the mutant enzyme remains unchanged
C1651A
-
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues
-
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues
-
the mutant shows the greatest decrease in inhibitory activity in the interferon-beta promoter activity assay
T312A/I313V/I353R
mutant lacks deubiquitinase activity, amino acid numbering based on polyprotein
T312A/I313V/I353R
-
mutant lacks deubiquitinase activity, amino acid numbering based on polyprotein
-
-
site-directed mutagenesis, active site cysteine mutant, forms a noncovalent complex with ubiquitin, crystal structure analysis
C112S
site-directed mutagenesis, the C112S mutant is monomeric, ubiquitin binding crystal structure analysis, overview